Compugen Ltd. (CGEN), a clinical-stage immuno-oncology company, carries a "Strong Buy" consensus among a small group of sell-side analysts. The five verified targets reviewed here range from $4.00 to $6.00, with a calculated mean of $4.60. This average analyst price target reflects a narrow but clearly bullish range.
The individual views include H.C. Wainwright at $4.00, Stifel at $4.00, and a third firm at $4.00, while Leerink Partners lowered its target to $5.00 from $13.00 in May 2026, and Lake Street initiated coverage at $6.00 in April 2026. That spread matters: the gap between the cautious $4.00 targets and Lake Street's $6.00 reflects differing assumptions about how much of the partnered pipeline value is already priced in.
One notable data point is the substantial downward revision at Leerink, which cut its target by more than 60%. That signals a more measured view of the pipeline's near-term catalysts even as the overall rating stayed constructive. No single target should be treated as a forecast of where the stock will trade.
The shares recently traded near $2.14, giving the company a market capitalization around $200 million. Reaching the $4.60 target would require a gain of roughly 115% from that level, which must be characterized as a very large move for any equity, and especially for a clinical-stage biotechnology company whose value is tied to discrete data readouts.
Compugen's position is unusual among small-cap biotechs because it is currently profitable on a trailing basis, with EPS (earnings per share) around $0.38 and trailing revenue near $74 million, driven in part by recognition of upfront and milestone payments from its Gilead licensing agreement. That license revenue can be lumpy, so investors should view near-term profitability in the context of milestone timing rather than steady-state earnings power.
The clearest catalyst is GS-0321 (formerly COM503), a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. The deal, signed in December 2023, carries up to $848 million in total value, including a $60 million upfront payment, a $30 million IND (Investigational New Drug) milestone, and tiered royalties on future sales. An ongoing Phase 1 dose-escalation trial continues to progress.
The company's broader pipeline also includes COM701, its anti-PVRIG antibody in the MAIA ovarian cancer study, and rilvegostomig, a PD-1/TIGIT bispecific partnered with AstraZeneca. A strong balance sheet with over $120 million in cash reduces the immediate risk of dilutive financing. Continued progress toward clinical milestones, or fresh data from partners, could support a re-rating.
The principal risk is clinical: an unfavorable or inconclusive data readout from GS-0321 or COM701 could materially reduce the pipeline's perceived value. Compugen is also heavily dependent on its partners, Gilead and AstraZeneca, for much of the development and commercialization economics, which limits its control over the pipeline's trajectory.
Valuation swings in small-cap biotech are often sharp. The stock's five-year beta near 2.8 underscores how much it can move with sector sentiment and data news. A broader pullback in risk appetite, or a decision by a partner to deprioritize a program, could compress the multiple and leave the shares well short of the $4.60 level.
The shares have traded in a 52-week range of roughly $1.43 to $3.24. The upper end of that range sits well below the $4.60 target, meaning the stock would need to break decisively above a prior high before approaching the analyst-derived objective. On the downside, the area near $1.43 to $1.50 has acted as a notable support level during recent volatility. Because these are relatively durable price zones rather than fast-moving indicator readings, they offer a useful structural framework for monitoring the stock forecast.
Analyst price targets generally reflect a research horizon of around 12 months, though individual firms may differ, and no horizon should be assumed for the $4.60 figure specifically. Investors should watch the next earnings report, scheduled for early November 2026, along with any updates on the GS-0321 Phase 1 dose-escalation trial and the COM701 MAIA-ovarian study's interim analysis. Milestone-triggered payments under the Gilead agreement, partner commentary on rilvegostomig, and any changes to analyst targets or ratings are also worth tracking.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name like CGEN, such tools can help traders spot shifting trends and momentum more efficiently than manual review. Traders can use these signals to discover opportunities, monitor existing positions, and react to changing market structure. Explore the AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.
The $4.60 central target is an arithmetic average of five current analyst price targets, and it implies a gain of roughly 115% from recent levels, a very large required move. The strongest supports are the partnered GS-0321 and rilvegostomig programs and a solid cash position, while the principal obstacles are binary clinical outcomes, partner dependency, and the stock's high volatility. Analysts agree the stock is undervalued relative to their targets, but their wide range of views from $4.00 to $6.00 reflects genuine uncertainty about the pipeline's ultimate value. Whether CGEN can reach $4.60 will depend far more on forthcoming data readouts than on near-term market sentiment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | -7.55% | ||
| ORMP - CGEN | 40% Loosely correlated | -0.48% | ||
| RCUS - CGEN | 37% Loosely correlated | +1.36% | ||
| RXRX - CGEN | 37% Loosely correlated | -1.65% | ||
| GHRS - CGEN | 36% Loosely correlated | -2.17% | ||
| AXON - CGEN | 36% Loosely correlated | +2.98% | ||
More | ||||